4869 recruiting. 4869 Phase 2, 1214 Phase 1, 215 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4869 | Recruiting 4869 |
| Phase 1 | 1214 | Recruiting 1214 |
| Phase 3 | 215 | Recruiting 215 |
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-11-03 |
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 31 | 2027-06-01 | 2026-10-22 |
| Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial Balstilimab, Biopsy Procedure, Biospecimen Collection - Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2027-05-25 | 2026-09-29 |
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-10-28 |
| Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2027-05-17 | 2026-10-21 |
| A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information Biospecimen Collection, Chest Radiography, Computed Tomography - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | Children's Oncology Group | 51 | 2027-05-15 | 2026-09-24 |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-26 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease Safusidenib - Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma | Phase 2 | Recruiting | Nuvation Bio Inc. | 40 | 2027-03-01 | 2026-10-20 |
| Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 15 | 2027-02-01 | 2025-03-30 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) Carboplatin, Paclitaxcel, Pembrolizumab - Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes | Phase 2 | Recruiting | Medical University of South Carolina | 55 | 2027-01-01 | 2026-10-15 |
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients Tamoxifen - Hypogonadism, Prostate Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 96 | 2026-12-31 | 2026-10-22 |
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy Lactulose - Cancer | Phase 1 / Phase 2 | Recruiting | University of Chicago | 55 | 2026-12-15 | 2026-06-16 |
| A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy - Non-Small Cell Lung Cancer, Metastatic Lung Cancer | Phase 2 | Recruiting | University of Chicago | 39 | 2026-12-12 | 2026-06-16 |
| ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer ANO31905, AG [gemcitabine+nab-paclitaxel], mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil] - Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Anova Innovation Limited | 84 | 2026-12-01 | 2026-10-23 |
| Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures Panitumumab-IRDye800, Pinpoint-IR9000 endoscopic/handheld device, Explorer Air camera - Brain Tumor | Phase 1 / Phase 2 | Recruiting | Stanford University | 12 | 2026-12-01 | 2026-09-29 |
| Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma Doxorubicin - Sarcoma | Phase 2 | Recruiting | University of Colorado, Denver | 20 | 2026-12-01 | 2026-02-05 |
Showing 20 of 4869. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (471) · Breast Neoplasms (431) · Colorectal Neoplasms (275) · Prostatic Neoplasms (259) · Leukemia, Myeloid, Acute (211) · Carcinoma, Hepatocellular (194) · Lung Neoplasms (182) · Pancreatic Neoplasms (178) · Neoplasm Metastasis (177) · Recurrence (177) · Multiple Myeloma (176) · Squamous Cell Carcinoma of Head and Neck (169) · Ovarian Neoplasms (163) · Stomach Neoplasms (158)
Neoplasms by Site (3226) · Neoplasms by Histologic Type (2488) · Hemic and Lymphatic Diseases (1116) · Neoplasms, Glandular and Epithelial (1112) · Digestive System Diseases (1063) · Digestive System Neoplasms (1047) · Immune System Diseases (875) · Carcinoma (851) · Immunoproliferative Disorders (834) · Lymphoproliferative Disorders (822) · Urogenital Diseases (779) · Urogenital Neoplasms (737) · Hematologic Diseases (702) · Lymphatic Diseases (692)
pembrolizumab (290) · Carboplatin (247) · Specimen Handling (229) · Cyclophosphamide (213) · Cisplatin (204) · Magnetic Resonance Spectroscopy (196) · Bevacizumab (155) · Gemcitabine (152) · Radiotherapy (148) · venetoclax (137) · Biopsy (132) · Drug Therapy (132) · Paclitaxel (132) · Nivolumab (128) · Dexamethasone (114)
M.D. Anderson Cancer Center (153) · National Cancer Institute (NCI) (114) · Memorial Sloan Kettering Cancer Center (105) · Sun Yat-sen University (103) · Fudan University (101) · Tianjin Medical University Cancer Institute and Hospital (49) · City of Hope Medical Center (44) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (43) · Institute of Hematology & Blood Diseases Hospital, China (41) · Mayo Clinic (41) · Merck Sharp & Dohme LLC (41) · Second Affiliated Hospital, Zhejiang University, School of Medicine (37) · The First Affiliated Hospital with Nanjing Medical University (36) · AstraZeneca (35) · Ruijin Hospital (35)
United States (2157) · China (1838) · France (369) · Spain (347) · Italy (288) · Australia (284) · South Korea (272) · Canada (263) · United Kingdom (243) · Germany (242) · Japan (176) · Netherlands (158) · Taiwan (158) · Belgium (131) · Poland (115)
Bing Xu (8) · Zhenfeng Zhang, MD, PhD (8) · Jason Wu (7) · Matthew Krebs, Dr (7) · Weidong Han, Ph.D (6)
PMID 41671463, PMID 35622074, PMID 40550489, PMID 40812353, PMID 17960615, PMID 33538338, PMID 37097003, PMID 40056080, PMID 16757203, PMID 19097774, PMID 19282026, PMID 21612974, PMID 23802653, PMID 26308596, PMID 26408225, PMID 29366520, PMID 30714987, PMID 30904387, PMID 30998813, PMID 32160294, PMID 32416453, PMID 33332189, PMID 34143971, PMID 34606846, PMID 36529152, PMID 37280366, PMID 38816232, PMID 38826786, PMID 38950555, PMID 39500789, PMID 40513054, PMID 40645505, PMID 40802906, PMID 41621809, PMID 41698326, PMID 41843779, PMID 41894687, PMID 41979863, PMID 42032732, PMID 42568612, PMID 5449164, PMID 10334539, PMID 10515382, PMID 10573044, PMID 10741392, PMID 10845900, PMID 11013273, PMID 11171826, PMID 11282341, PMID 11282421
2025 (125), 2023 (107), P30CA033572 (39), U10CA180888 (18), P30CA138292 (17), P30CA060553 (13), U10CA180886 (11), U10CA180820 (10), 2017 (8), 2018 (8), 2019 (8), U10CA180868 (8), P30CA012197 (7), P30CA093373 (6), UM1CA186691 (6)